Current Issue
VOL 12 NO 3 • APR 2021
This issue’s cover illustration depicts highlights from JADPRO Live. Artwork by Harborside 2021.EditorialBeth Faiman, PhD, MSN, APRN-BC, AOCN®, FAANThis past October, over 1,000 nurse practitioners, PAs, pharmacists, and other oncology professionals attended the eighth annual JADPRO Live conference, which went virtual for the first time. Amid uncertainty and unprecedented challenges from the COVID-19 pandemic, oncology advanced practitioners...
Meeting ReportPresented by Gabrielle Zecha,(1) PA-C, MHA, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, David Johnson,(3) PA-C, and Sara Toth,(4) RN, APRN, FNP-C, AOCNP®, AGN-BCAs health-care systems face challenges never before encountered in the era of modern medicine, advanced practitioners (APs) are playing critical roles in developing protocols, managing health-care teams, and delivering patient care. JADPRO Live 2020 kicked off its virtual meeting with a discussio...
Meeting ReportPresented by Laura J. Zitella,(1) MS, RN, ACNP-BC, AOCN®, and Tatiana M. Prowell,(2) MDWhile cancer treatments continue to evolve at a rapid pace, the culture of medicine is rife with outdated norms that reinforce gender and racial disparities, explains Tatiana M. Prowell, MD, of Johns Hopkins Kimmel Comprehensive Cancer Center.
During JADPRO Live Virtual 2020, Conference Chair Lau...
Meeting ReportPresented by Jason Astrin, DMSc, MBA, PA-C, DFAAPAAdvanced practitioners drive revenue for oncology practices, but calculating their true value is a complicated proposition compared with other care providers. During JADPRO Live Virtual 2020, Jason Astrin, DMSc, MBA, PA-C, DFAAPA, Director of APP Services, The US Oncology Network, differentiated ...
Meeting ReportPresented by Andrew S. Guinigundo, MSN, RN, CNP, ANP-BCAs the saying goes, you only have one chance to make a first impression. Mastering the “elevator pitch” can be an invaluable skill for advanced practitioners. During JADPRO Live Virtual 2020, Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, defined the concept of an elevator pitch and its application ...
Meeting ReportPresented by Jessica Shank Coviello, DNP, APRN, ANP-BC, and Kejal Amin, PharmD, MBA, BCOPThe connection between cancer and cardiovascular disease has been well established in medicine, but their shared pathophysiologic patterns remain less understood. During the JADPRO Live Virtual 2020 conference, Jessica Shank Coviello, DNP, APRN, ANP-BC, of Yale University School of Nursing, and K...
Meeting ReportPresented by Lorena A. Wright, MD, FACEUnderstanding the optimal management of hyperglycemia in patients with cancer is an essential responsibility of advanced practitioners. During JADPRO Live Virtual 2020, Lorena A. Wright, MD, FACE, of the University of Washington Diabetes Institute in Seattle, discussed the importance of glycemic ...
Meeting ReportPresented by Val R. Adams, PharmD, FCCP, FHOPA, BCOPBoth CHEST and National Comprehensive Cancer Network (NCCN) guidelines can help advanced practitioners determine which patients with cancer should be treated with a direct oral anticoagulant (DOAC), but optimizing the risk-to-benefit ratio must still be done at the individual patient level, accor...
Meeting ReportPresented by Laura J. Zitella, MS, RN, ACNP-BC, AOCN®With up to 50% of hospitalized patients experiencing low blood platelet count, thrombocytopenia is a very common condition. During JADPRO Live Virtual 2020, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California, San Francisco, discussed the most important causes of thrombocyto...
Meeting ReportPresented by Veena Shankaran, MD, MSFinancial toxicity among cancer patients is a growing and complex problem, affecting people across all socioeconomic strata with various types of insurance.
During JADPRO Live Virtual 2020, Veena Shankaran, MD, MS, of the University of Washington, Seattle Cancer Care Alliance, and Fred Hutchinson...
Meeting ReportPresented by Kirollos S. Hanna, PharmD, BCPS, BCOPDespite the COVID-19 pandemic, numerous oncology drugs have been approved by the U.S. Food & Drug Administration (FDA) over the past 12 months for initial or expanded indications for the management of patients with solid tumors (Table 1).
During JADPRO Live Virtual 2020, Kirollos S. Hanna, P...
Meeting ReportPresented by Heidi D. Finnes, PharmD, BCOP, FHOPAFrom late 2019 to late 2020, the U.S. Food & Drug Administration (FDA) approved a number of medications for the management of patients with hematologic malignancies, including drugs for lymphoma, myeloma, myelodysplastic syndrome, and sickle cell anemia. During JADPRO Live Virtual 2020, Heidi...
Meeting ReportPresented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Allyson Price,(3) MPAS, PA-CAs oncology continues to move towards precision medicine with targeted therapies, biomarker expression is playing an increasingly important role. In a session led by Sandra E. Kurtin, PhD, ANP-C, AOCN®, during JADPRO Live Virtual 2020, Alyssa Henglefelt, PharmD, BCOP, HonorHealth, Virginia G. Pip...
Meeting ReportPresented by Lisa Kottschade, APRN, MSN, CNPImmune checkpoint inhibitors have been successful in advancing the field of oncologic treatment, but there is a dark side to these drugs. Immune-related adverse events (irAEs) that occur via activation of a patient’s immune system can affect any tissue, organ, or body system and pose distinct cha...
Meeting ReportPresented by Richard Pazdur, MDAs the first U.S. Food & Drug Administration (FDA) Inter-Center Institute, the Oncology Center of Excellence (OCE) fosters a unified interaction between the three FDA centers: the Center for Biologics Evaluation and Research (CBER); the Center for Drug Evaluation and Research (CDER); and the ...
Meeting ReportPresented by Brenda Martone, MSN, ANP-BC, AOCNP®With the introduction of novel agents for the treatment of advanced prostate cancer, the range of options with notable benefits has widened. The armamentarium now includes second-generation androgen receptor–targeting agents and several chemotherapeutics as well as new drugs targeting other oncog...
Meeting ReportPresented by Rasheda Persinger, AGNP-CIn the past 15 years, the number of targeted therapies for non–small cell lung cancer (NSCLC) has grown from 0 to 17, as the list of oncogenic mutations continues to expand in this heterogeneous group of lung cancers.
At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, of Johns Hopkins Univer...
Meeting ReportPresented by Casey Fazer-Posorske, PA-CHead and neck cancer accounts for more than 550,000 cases and 380,000 deaths annually around the world. During JADPRO Live Virtual 2020, Casey Fazer-Posorske, PA-C, of Mayo Clinic, described the various types of head and neck cancers along with associated treatments and side-effect management. Ms...
Meeting ReportPresented by Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®The death rate from hepatocellular cancer (HCC) has more than doubled in the past 30 years as the incidence of this disease continues to rise worldwide. However, the recent approvals of targeted agents and immunotherapies have dramatically changed the treatment landscape of HCC and should impact ...
Meeting ReportPresented by Kristen O’Hagan, ANP-BC, MS, AOCNP®During JADPRO Live Virtual 2020, Kristen O’Hagan, ANP-BC, MS, AOCNP®, of Memorial Sloan Kettering Cancer Center, described the presentation, diagnosis, and treatment algorithms of rare gastrointestinal tumors, including neuroendocrine tumors and cancers of the appendix, gallbladder, and bile duct...
Meeting ReportPresented by Kathleen Burns, AGACNP-BC, OCN®Over the past 10 years, the arrival of immunotherapies and targeted agents has extended the survival and improved the quality of life for patients with renal cell carcinoma (RCC), but these novel therapies have also introduced challenging new side effects.
During JADPRO Live Virtual 2020, Kathlee...
Meeting ReportPresented by Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MSA rare tumor constituting less than 1% of all cancer types, sarcoma presents unique challenges for both patients and health-care providers throughout the treatment course.
During JADPRO Live Virtual 2020, Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS, of The University of Texas MD An...
Meeting ReportPresented by Sandra E. Kurtin, PhD, ANP-C, AOCN® Treatment of chronic lymphocytic leukemia (CLL) is becoming increasingly personalized, relying on both the molecular attributes of the disease and patient characteristics.
During JADPRO Live Virtual 2020, Sandra Kurtin, PhD, ANP-C, AOCN®, of the University of Arizona Cancer Center, identified key...
Meeting ReportPresented by Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®Vast improvements in the diagnosis and management of amyloidosis have underscored the importance of prompt diagnosis and effective treatment. During JADPRO Live Virtual 2020, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, of Cleveland Clinic Taussig Cancer Institute, and Tiffany Richards, PhD, ...
Meeting ReportPresented by Maritza Alencar, DNP, MBA, APRN-BC, BMTCNAs the number of recipients continues to rise, recent advances in hematopoietic stem cell transplant have led to improved outcomes. During JADPRO Live Virtual 2020, Maritza Alencar, DNP, MBA, APRN-BC, BMTCN, of the University of Miami Sylvester Comprehensive Cancer Center, described advances in t...
Meeting ReportPresented by Ravi Krishnadasan, MD, FACPAlthough hemolytic anemia is most commonly associated with autoimmune causes, not all hemolysis can be diagnosed with a positive direct antiglobulin (Coombs) test.
During JADPRO Live Virtual 2020, Ravi Krishnadasan, MD, FACP, of The University of Arizona Cancer Center, focused on nonimmune hemoly...
